Inclusion Criteria:~* Participated in a double-blind treatment period of a sponsor-approved originating
donanemab trial, for example the TRAILBLAZER-ALZ study.~* Have a study partner~* Stable symptomatic Alzheimer's
Disease (AD) medications and other medication that may impact cognition for at least 30 days prior to
randomization into Part A~
